Title: Cetuximab
CAS Registry Number: 205923-56-4
CAS Name: Anti-(human epidermal growth factor receptor) immunoglobulin G1 (human-mouse monoclonal C225 g1-chain), disulfide with human-mouse monoclonal C225 k-chain, dimer
Additional Names: C225
Manufacturers' Codes: IMC-C225
Trademarks: Erbitux (ImClone)
Literature References: Chimeric monoclonal antibody directed against human epithelial growth factor receptor (EGFR). Prepn: N. I. Goldstein et al., WO 9640210 (1995 to Imclone and MRC); eidem, Clin. Cancer Res. 1, 1311 (1995). Antitumor activity: J. Mendelson, ibid. 6, 747 (2000). Clinical pharmacokinetics: F. Robert et al., J. Clin. Oncol. 19, 3234 (2001); in combination with irinotecan: C. Delbaldo et al., Eur. J. Cancer 41, 1739 (2005). Clinical trial in head and neck cancer: B. Burtness et al., J. Clin. Oncol. 23, 8646 (2005); in combination with radiotherapy: J. A. Bonner et al., N. Engl. J. Med. 354, 567 (2006). Review of mechanism of action: R. S. Herbst et al., Expert Opin. Biol. Ther. 1, 719-732 (2001); J. Baselga, Eur. J. Cancer 37, S16-S22 (2001); of pharmacology and clinical studies: R. S. Herbst, C. J. Langer, Semin. Oncol. 29, Suppl. 4, 27-36 (2002); of use in colorectal cancer: S.-F. Wong, Clin. Ther. 27, 684-694 (2005).
Therap-Cat: Antineoplastic.
Keywords: Antineoplastic; Monoclonal Antibodies.

Others monographs:
LovastatinZymosanAmmonium PhosphotungstateRoxithromycin
Neomycin UndecylenateViomycinNiclosamideCarbon Disulfide
Tetralin®FlazasulfuronAnisotropine MethylbromideZirconium Hydroxide
©2016 DrugLead US FDA&EMEA